Most primary and recurrent ovarian cancers expressed estrogen receptor (ER; 67.0% and 72.9%, respectively) or gonadotropin releasing hormone receptor (GnRHR; 87.9% and 85%, respectively), while progesterone receptor (PR) remained at low levels in both primary and recurrent specimens (9.3% and 6.7%, respectively) (Table 2). This evidence concerns the gene PGR and ovarian carcinoma.